Global Leading Market Research Publisher QYResearch announces the release of its latest report “Capivasertib – Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032”.
The PI3K/AKT/mTOR signaling pathway represents one of the most frequently dysregulated oncogenic axes in human cancer, yet therapeutic targeting of this pathway has proven exceptionally challenging. First-generation mTOR inhibitors delivered modest clinical benefit constrained by feedback activation of upstream signaling. Pan-PI3K inhibitors encountered toxicity limitations that narrowed therapeutic windows. The AKT node—situated at the critical junction of pathway signal integration—has long represented an attractive but elusive drug target. Capivasertib, the world’s first approved AKT kinase inhibitor, has finally addressed this pharmacologic gap, delivering pathway inhibition with clinical proof-of-concept across multiple solid tumor types defined by PIK3CA, AKT1, or PTEN alterations. Based on current situation and impact historical analysis (2021-2025) and forecast calculations (2026-2032), this report provides a comprehensive analysis of the global Capivasertib market, examining how this AKT inhibitor, PI3K/AKT pathway targeted therapy, and precision oncology therapeutic is positioned within the rapidly evolving landscape of genomically-directed cancer therapy.
[Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)]
https://www.qyresearch.com/reports/6700029/capivasertib
The global market for Capivasertib was estimated to be worth USD 728 million in 2025 and is projected to reach USD 2,733 million by 2032, advancing at a robust CAGR of 14.7% from 2026 to 2032. In 2025, global production reached approximately 1.8 million bottles. This near-fourfold expansion over seven years reflects not merely volume growth from the initial approved indication but the progressive clinical validation and regulatory expansion across multiple tumor types, companion diagnostic co-development, and market access establishment across major global pharmaceutical markets.
Mechanism of Action and Pharmacological Rationale
Capivasertib is an oral, highly selective ATP-competitive AKT kinase inhibitor that potently inhibits the activities of all three AKT isoforms (AKT1, AKT2, and AKT3). By blocking AKT phosphorylation and subsequent kinase activity, it disrupts the abnormal activation of the PI3K/AKT signaling pathway that drives tumor cell proliferation, survival, invasion, and metastasis across a broad spectrum of human malignancies. The drug is primarily developed for patients with solid tumors harboring genetic alterations in PIK3CA (encoding the p110α catalytic subunit of PI3K), AKT1 (the E17K activating mutation), or PTEN (loss-of-function mutations or deletions that relieve negative regulation of PIP3 signaling)—biomarkers that collectively identify the patient population most likely to derive clinical benefit from AKT pathway inhibition.
Clinically, Capivasertib is primarily used in combination with fulvestrant, a selective estrogen receptor degrader (SERD), for the treatment of HR-positive, HER2-negative advanced breast cancer following progression on or after endocrine therapy. The rationale for this combination derives from the well-characterized crosstalk between estrogen receptor signaling and the PI3K/AKT pathway: estrogen receptor activation stimulates PI3K pathway signaling through non-genomic effects and transcriptional regulation of receptor tyrosine kinases, while AKT-mediated phosphorylation of the estrogen receptor itself promotes ligand-independent transcriptional activation. Combined inhibition of both pathways addresses this bidirectional signaling escape mechanism, overcoming endocrine resistance driven by PI3K/AKT pathway hyperactivation—the most common mechanism of acquired resistance to aromatase inhibitors and selective estrogen receptor modulators.
Beyond breast cancer, Capivasertib is under investigation in various tumor types including prostate cancer (where PTEN loss occurs in approximately 40-50% of metastatic castration-resistant prostate cancer) and colorectal cancer (where PIK3CA mutations occur in 15-20% of tumors), providing molecularly targeted cancer therapy options for populations with limited standard-of-care alternatives.
Industry Segmentation: Comparing AKT Inhibition Across Tumor Types—The Mutational Landscape
An exclusive analytical perspective distinguishes between three deployment contexts for Capivasertib based on underlying pathway alterations—a segmentation that fundamentally shapes addressable patient populations and commercial opportunity.
PIK3CA-mutant tumors represent the largest genomically-defined population. PIK3CA mutations occur in approximately 40% of HR+/HER2- breast cancers, 15-20% of colorectal cancers, and across multiple additional solid tumor types. These activating mutations confer constitutive PI3K pathway signaling and are associated with endocrine resistance in breast cancer. The CAPItello-291 Phase III trial demonstrated that adding Capivasertib to fulvestrant significantly improved progression-free survival in the overall population (HR 0.60), with the greatest benefit observed in the PIK3CA/AKT1/PTEN-altered subgroup (HR 0.50). This biomarker-defined efficacy supports a precision oncology treatment approach that maximizes clinical benefit while avoiding exposure in patients unlikely to respond.
AKT1 E17K-mutant tumors represent a rare but uniquely responsive population. The AKT1 E17K mutation, occurring in approximately 4% of breast cancers, 2% of endometrial cancers, and sporadically across other tumor types, results in constitutive AKT membrane localization and pathway activation. The mutation’s rarity creates both a clinical challenge—requiring broad genomic screening for case identification—and a therapeutic opportunity, as activating mutations in the drug target itself typically confer exceptional sensitivity to targeted inhibition.
PTEN-deficient tumors represent the largest aggregate population but the most heterogeneous biology. PTEN loss occurs through multiple mechanisms—homozygous deletion, loss-of-function mutation, and epigenetic silencing—in approximately 50% of prostate cancers, 30-40% of glioblastomas, and across multiple additional tumor types. PTEN loss activates the PI3K/AKT pathway through failure to dephosphorylate PIP3, the lipid second messenger that activates AKT signaling. The clinical challenge in this population lies in the heterogeneity of PTEN loss mechanisms and the variable correlation between PTEN immunohistochemistry, PTEN genomic status, and actual pathway dependence.
Competitive Dynamics: First-Mover Advantage in an Oligopolistic Market
Capivasertib has established a core position in HR+/HER2- advanced breast cancer through its first-mover advantage as the world’s first approved AKT inhibitor coupled with a clear, co-developed companion diagnostic strategy. The current market landscape is oligopolistic—as the only approved AKT inhibitor, Capivasertib faces limited direct competition, with few similar drugs in late-stage clinical development. This first-to-market positioning, combined with robust Phase III clinical evidence and the commercial infrastructure of AstraZeneca’s established oncology franchise, creates substantial barriers to competitive entry even as additional AKT inhibitors potentially approach regulatory submission.
The targeted cancer drug market for PI3K/AKT pathway inhibitors also includes indirect competitors: alpelisib (a PI3Kα-selective inhibitor approved for PIK3CA-mutant HR+/HER2- breast cancer) and everolimus (an mTORC1 inhibitor approved for HR+/HER2- breast cancer in combination with exemestane). Capivasertib’s differentiation relative to alpelisib lies in its tolerability profile—AKT inhibition appears associated with lower rates of the hyperglycemia that limits alpelisib dosing and adherence—and potentially broader activity against tumors with AKT1 mutations and PTEN loss, which are not specifically targeted by PI3Kα inhibition.
Market Segments
The Capivasertib market features AstraZeneca as the sole global developer and commercial manufacturer.
Segment by Type
- 160 mg: Standard maintenance dosage form for continuous daily administration.
- 200 mg: Alternative dosage strength supporting dose individualization based on tolerability and concomitant medication profiles.
Segment by Application
- HR-Positive, HER2-Negative Advanced Breast Cancer: The initial approved indication and current dominant revenue driver, addressing a large population of endocrine-resistant patients.
- Metastatic Prostate Cancer: High-value expansion indication leveraging the high prevalence of PTEN loss in this tumor type.
- Advanced Colorectal Cancer: Expansion indication with substantial addressable population driven by PIK3CA mutation prevalence.
- Others: Encompassing pan-tumor development across additional solid tumor types with PI3K/AKT pathway alterations.
Strategic Outlook
With gradual market access establishment across major global regions including FDA and EMA approvals, the popularization of next-generation sequencing panels that reliably detect PIK3CA/AKT1/PTEN alterations, and the continuous expansion of indications through the ongoing clinical development program, Capivasertib is rapidly penetrating from second-line breast cancer treatment into additional tumor types. The Capivasertib market at USD 728 million in 2025 projects to reach USD 2,733 million by 2032, supported by significant long-term commercialization potential. The drug is expected to become a key product within AstraZeneca’s oncology portfolio, complementing existing positions in HER2-directed therapy (trastuzumab deruxtecan), endocrine therapy (fulvestrant), and PARP inhibition (olaparib) to create a comprehensive precision oncology platform addressing the needs of genomically-defined breast cancer subpopulations.
Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:
QY Research Inc.
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
E-mail: global@qyresearch.com
Tel: 001-626-842-1666(US)
JP: https://www.qyresearch.co.jp
